These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25653396)

  • 1. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
    Sarrazin C; Dierynck I; Cloherty G; Ghys A; Janssen K; Luo D; Witek J; Buti M; Picchio G; De Meyer S
    J Clin Microbiol; 2015 Apr; 53(4):1264-9. PubMed ID: 25653396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Gilles L; De Locht P; Picchio G; De Meyer S; Sarrazin C
    J Clin Virol; 2015 Nov; 72():133-40. PubMed ID: 26513763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
    Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
    Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
    Cloherty G; Cohen D; Sarrazin C; Wedemeyer H; Chevaliez S; Herman C; Bernstein B; Pawlotsky JM
    Antivir Ther; 2015; 20(2):177-83. PubMed ID: 24941124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment.
    Wiesmann F; Naeth G; Berger A; Hirsch HH; Regenass S; Ross RS; Sarrazin C; Wedemeyer H; Knechten H; Braun P
    Med Microbiol Immunol; 2016 Jun; 205(3):263-8. PubMed ID: 26666643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
    Matsuura K; Tanaka Y; Hasegawa I; Ohno T; Tokuda H; Kurbanov F; Sugauchi F; Nojiri S; Joh T; Mizokami M
    J Clin Microbiol; 2009 Feb; 47(2):385-9. PubMed ID: 19091819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
    Vermehren J; Bourlière M; Pol S; Marcellin P; Hyland RH; Jiang D; Brainard DM; Zeuzem S; Welzel TM
    J Clin Virol; 2017 Apr; 89():51-56. PubMed ID: 28259054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Picchio G; Sarrazin C
    Antivir Ther; 2014; 19(6):559-67. PubMed ID: 24584086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
    Maasoumy B; Cobb B; Bremer B; Luk K; Halfon P; Aslam S; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2014 Jan; 39(1):85-92. PubMed ID: 24206524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V; Di Paolo D; Di Carlo D; Micheli V; Tontodonati M; De Leonardis F; Aragri M; Antonucci FP; Di Maio VC; Mancon A; Lenci I; Manunta A; Taliani G; Di Biagio A; Nicolini LA; Nosotti L; Sarrecchia C; Siciliano M; Landonio S; Pellicelli A; Gasbarrini A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
    Halfon P; Pénaranda G; Bourlière M; Khiri H; Masseyeff MF; Ouzan D
    J Med Virol; 2006 Feb; 78(2):208-15. PubMed ID: 16372298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
    Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.